Immorta Bio Announces First Human Administration of SenoMune™-0257 Immunotherapy
Immorta Bio has announced the first human administration of its investigational immunotherapy, SenoMune™-0257. The treatment, a proprietary nine-amino-acid peptide designed to stimulate the immune system to eliminate senescent 'zombie' cells, was administered to a patient with advanced cancer on October 29, 2026, in Mexico. The clinical study is an independently conducted, investigator-initiated trial at Integrative Cancer Centers of America (ICCA). While the initial phase focuses on oncology to demonstrate senolytic capabilities, Immorta Bio intends to expand the platform's application to a wide range of age-related conditions, including neurodegenerative, cardiovascular, and metabolic diseases.
Topics: aging research cancer treatment clinical trials immunotherapy senolytic therapy